Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) FCF Margin (2016 - 2025)

Historic FCF Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 31.42%.

  • China Pharma Holdings' FCF Margin fell 279900.0% to 31.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.03%, marking a year-over-year increase of 160600.0%. This contributed to the annual value of 11.89% for FY2024, which is 17400.0% down from last year.
  • China Pharma Holdings' FCF Margin amounted to 31.42% in Q3 2025, which was down 279900.0% from 28.6% recorded in Q2 2025.
  • China Pharma Holdings' FCF Margin's 5-year high stood at 52.11% during Q3 2023, with a 5-year trough of 72.04% in Q1 2023.
  • Moreover, its 5-year median value for FCF Margin was 7.86% (2024), whereas its average is 10.17%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -595500bps in 2022, then skyrocketed by 538100bps in 2023.
  • China Pharma Holdings' FCF Margin (Quarter) stood at 7.1% in 2021, then surged by 395bps to 20.95% in 2022, then tumbled by -106bps to 1.25% in 2023, then skyrocketed by 1408bps to 16.34% in 2024, then plummeted by -292bps to 31.42% in 2025.
  • Its last three reported values are 31.42% in Q3 2025, 28.6% for Q2 2025, and 10.41% during Q1 2025.